BioVie Inc., a biopharmaceutical company, has filed a supplement to its definitive proxy statement with the U.S. Securities and Exchange Commission (SEC) for its upcoming Annual Meeting of Stockholders scheduled for November 27, 2024. The supplement, dated September 27, 2024, provides updated information regarding the equity awards for the company's named executive officers as of June 30, 2024, and details the compensation for non-employee directors during the fiscal year ended June 30, 2024. It also amends disclosures under the heading 'Certain Relationships and Related Transactions, and Director Independence'. The supplement reveals that named executive officers held stock options to purchase a total of 185,134 shares of common stock with an aggregate grant date fair value of approximately $5.6 million. The document also outlines the compensation structure for...Show More

BioVie Inc., a biopharmaceutical company, has filed a supplement to its definitive proxy statement with the U.S. Securities and Exchange Commission (SEC) for its upcoming Annual Meeting of Stockholders scheduled for November 27, 2024. The supplement, dated September 27, 2024, provides updated information regarding the equity awards for the company's named executive officers as of June 30, 2024, and details the compensation for non-employee directors during the fiscal year ended June 30, 2024. It also amends disclosures under the heading 'Certain Relationships and Related Transactions, and Director Independence'. The supplement reveals that named executive officers held stock options to purchase a total of 185,134 shares of common stock with an aggregate grant date fair value of approximately $5.6 million. The document also outlines the compensation structure for non-employee directors, including stock and option awards, with a total of 276,581 stock options outstanding to directors as of June 30, 2024, valued at approximately $8.2 million. Additionally, the supplement mentions the company's 2019 Omnibus Equity Incentive Plan, which allows for the issuance of up to 654,000 shares of common stock, with 8,721 shares available for new awards as of June 30, 2024. The supplement should be read in conjunction with the original proxy statement to provide stockholders with comprehensive information ahead of the Annual Meeting.